Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010052556 - TREATMENT WITH ANTI-ALPHA2 INTEGRIN ANTIBODIES

Publication Number WO/2010/052556
Publication Date 14.05.2010
International Application No. PCT/IB2009/007351
International Filing Date 05.11.2009
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/46 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 1/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
08for nausea, cinetosis or vertigo; Antiemetics
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants
  • GLENMARK PHARMACEUTICALS S.A. [CH]/[CH] (AllExceptUS)
  • MOTTL, Harald [DE]/[CH] (UsOnly)
Inventors
  • MOTTL, Harald
Agents
  • SCHÖLLHORN, Andreas
Priority Data
61/111,93206.11.2008US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT WITH ANTI-ALPHA2 INTEGRIN ANTIBODIES
(FR) TRAITEMENT UTILISANT DES ANTICORPS ANTI-INTÉGRINE ALPHA 2
Abstract
(EN)
Description of methods for the treatment of cancer. More specifically methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin' s lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/ follicular NHL; intermediate grade diffuse NHL, high grade immunoblastic NHL; high grade lymphoblastic NHL, high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia,- chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to alpha2betal integrin.
(FR)
L'invention concerne des méthodes de traitement du cancer. Elle concerne plus spécifiquement de méthodes de traitement, par l'administration d'anticorps dirigés contre l'intégrine alpha 2 bêta 1, de cancers sélectionnés dans le groupe constitué par le carcinome squameux, le cancer du poumon, y compris le cancer du poumon à petites cellules, un cancer du poumon autre qu'à petites cellules, l'adénocarcinome du poumon et le carcinome squameux du poumon, le cancer du péritoine, le carcinome hépatocellulaire, l'adénome gastrique ou cancer de l'estomac, y compris le cancer gastro-intestinal, le cancer du pancréas, le glioblastome, le cancer du col de l'utérus, le cancer de l'ovaire, le cancer du foie, le cancer de la vessie, l'hépatome, le cancer du sein, le cancer du côlon, le cancer colorectal, le carcinome de l'endomètre ou du col de l'utérus, le carcinome des glandes salivaires, le cancer du rein ou l'adénocarcinome du rein, le cancer du foie, le cancer de la prostate, le cancer de la vulve, le cancer de la thyroïde, le carcinome hépatique et divers types de cancers de la tête et de la nuque, ainsi que le lymphome B, y compris le lymphome non hodgkinien (LNH) bien différencié/nodulaire; le LNH lymphocytaire à petits lymphocytes; le LNH modérément différencié/nodulaire; le LNH nodulaire; le LNH modérément différencié diffus, le LNH immunoblastique peu différencié; le LNH lymphoblastique peu différencié, le LNH à petites cellules non clivées peu différencié; le NHL à masse tumorale volumineuse; le lymphome à cellules du manteau; le lymphome lié au SIDA; et la macroglobulinémie de Waldenstrom, la leucémie lymphocytaire chronique; la leucémie lymphoblastique aiguë; la leucémie à tricholymphocytes; la leucémie myéloblastique chronique; et le trouble lymphoprolifératif post-transplantation, ainsi que la prolifération vasculaire anormale associée à des phacomatoses, l'œdème tel que celui associé à des tumeurs du cerveau, le syndrome de Meigs, le mélanome, le mésothéliome, le myélome multiple, le fibrosarcome, l'ostéosarcome et le carcinome épidermoïde.
Latest bibliographic data on file with the International Bureau